Clinical Data Major trial launched to explore GLP-1 benefit in dementia PharmaphorumA $100m trial has been launched to see if lifestyle changes coupled with GLP-1 agonists or similar incretins can reduce the risk of dementia.NeuroscienceRead full story pharminent July 13, 2026 (Last updated: July 14, 2026) Pharmaphorum A $100m trial has been launched to see if lifestyle changes coupled with GLP-1 agonists or similar incretins can reduce the risk of dementia. Neuroscience Read full story Post navigation Previous: FDA posts new rejection letters days after confirming pauseNext: Germany approves healthcare costs overhaul despite significant pharma opposition Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026